Akouos, Inc. (AKUS)
| Market Cap | 610.64M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 15.33M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $17.76 |
| Previous Close | $17.76 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 17.51 |
| Day's Range | 17.39 - 18.47 |
| Day's Volume | 62,316 |
| 52-Week Range | 17.03 - 26.92 |
News
There are no news available yet.
About AKUS
Akouos, a precision genetic medicine company, develops gene therapies to restore, improve, and preserve physiologic hearing for people worldwide. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate, AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. Akouos has strategic partnerships with Massachusetts Eye and Ear and Lonza, Inc. The company was founded in 2016 and is headquartered in ... [Read more...]
| Industry Biotechnology | IPO Date Jun 26, 2020 |
| CEO Dr. Emmanuel Simons M.B.A., Ph.D. | Employees 54 |
| Stock Exchange NASDAQ | Ticker Symbol AKUS |
Analyst Forecasts
According to 4 analysts, the average rating for Akouos stock is "Strong Buy." The 12-month stock price forecast is 33.00, which is an increase of 85.81% from the latest price.